Triple Therapy with Azacitidine, Venetoclax and Gilteritinib as a Therapeutic Option for Adult Patients with Refractory/Relapsed FLT3 Mutated Acute Myeloid Leukemia – A Single Center Experience
Documenta Haematologica - Revista Romana de Hematologie · 23.06.2026 · 4 (2) · 49-55
DOI: 10.59854/dhrrh.2026.4.2.49 ↗Kurz gefasst
Fachartikel in der Zeitschrift Documenta Haematologica - Revista Romana de Hematologie, online erschienen am 23.06.2026. Verfasst von Dana FRANGU und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
FLT3 mutations occur in approximately 30% of acute myeloid leukemia (AML) cases and are associated with high relapse rates and poor prognosis. While second-generation inhibitors like gilteritinib have improved outcomes in the relapsed/refractory (R/R) setting, therapeutic resistance remains a significant challenge. This study evaluates the real-world experience of a single center using an off-label triplet regimen (Azacitidine, Venetoclax and Gilteritinib) as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Materials and Methods: We conducted a retrospective, observational study between March 2022 and September 2025. Out of 78 identified FLT3-positive AML patients, 8 patients with R/R disease received the triplet therapy following partial response or disease progression on gilteritinib monotherapy.
Results
Within the subgroup who experienced disease progression under gilteritinib (n = 4 of 8), all patients achieved complete remission (CR) after receiving triple therapy and successfully underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Regarding the safety profile, 63% of patients developed grade 3–4 hematologic toxicities (febrile neutropenia, anemia, thrombocytopenia), while hepatic cytolysis remained mild (grade 1–2), although it was observed in all patients (n = 8). At a median follow-up of 9 months, 75% of patients who underwent allo-HSCT post-triplet therapy remained alive.
Conclusions
Our findings suggest that the triplet combination of azacitidine, venetoclax and gilteritinib is a highly effective salvage strategy. Although careful monitoring is required due to moderate toxicities, particularly hematologic adverse events, it is a viable bridge to transplant for R/R FLT3-mutated AML patients who fail standard monotherapy.
Zitieren
APA
FRANGU, D., CONSTANTIN, B., ANDRUNACHE, A., HIRJAN, R., CIRSTEA, M., IONESCU, B., STANCIOAICA, C., GHIAUR, A., & TATIC, A. (2026). Triple Therapy with Azacitidine, Venetoclax and Gilteritinib as a Therapeutic Option for Adult Patients with Refractory/Relapsed FLT3 Mutated Acute Myeloid Leukemia – A Single Center Experience. Documenta Haematologica - Revista Romana de Hematologie, 4(2), 49-55. https://doi.org/10.59854/dhrrh.2026.4.2.49
Vancouver
FRANGU D, CONSTANTIN B, ANDRUNACHE A, HIRJAN R, CIRSTEA M, IONESCU B, et al. Triple Therapy with Azacitidine, Venetoclax and Gilteritinib as a Therapeutic Option for Adult Patients with Refractory/Relapsed FLT3 Mutated Acute Myeloid Leukemia – A Single Center Experience. Documenta Haematologica - Revista Romana de Hematologie. 2026;4(2):49-55. doi:10.59854/dhrrh.2026.4.2.49
BibTeX
@article{FRANGU2026,
author = {FRANGU, Dana and CONSTANTIN, Bianca and ANDRUNACHE, Andreea and HIRJAN, Roxana and CIRSTEA, Mihaela and IONESCU, Bogdan and STANCIOAICA, Camelia and GHIAUR, Alexandra and TATIC, Aurelia},
title = {Triple Therapy with Azacitidine, Venetoclax and Gilteritinib as a Therapeutic Option for Adult Patients with Refractory/Relapsed FLT3 Mutated Acute Myeloid Leukemia – A Single Center Experience},
journal = {Documenta Haematologica - Revista Romana de Hematologie},
year = {2026},
volume = {4},
number = {2},
pages = {49--55},
doi = {10.59854/dhrrh.2026.4.2.49}
}
EUVIMED